This Just out on Yahoo Finance and Marketwire PORT HUENEME, CA--(Marketwire -11/22/11)- Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH.V - News) (Pinksheets: SBOTF.PK - News) is pleased to report two recent news stories on the company, by the National Cancer Institute (NCI) and in Popular Science magazine. The NCI story is a Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) "Success Story" featuring Stellar's technology platform, NCI SBIR awards and recent corporate partnerships. The NCI's prestigious SBIR and STTR programs "foster research and development for anticancer agents, biomarkers, informatics, medical devices, nanotechnology, proteomics, pharmacodynamics, and many other biotechnologies and programs designed to prevent, diagnose, and treat cancer." The NCI Success Story on Stellar can be found here: http://sbir.cancer.gov/success/stories/stellar/stellar.asp or through http://sbir.cancer.gov/success/ Popular Science magazine's article "How Mollusk Blood Could Cure Cancer" covered the role of keyhole limpet hemocyanin (KLH) as an essential component in cancer vaccine research and Stellar's sustainable aquaculture practices. Stellar notes that the Popular Science story included one error. Contrary to the article's report, Stellar's current manufacturing capacity (not output) is between one and two kilograms of KLH per year. The Popular Science story appears in both the December 2011 print edition (page 17) and in the magazine's POPSCI website. Read here Stellar Executive VP, Corporate Development & Finance, Darrell Brookstein, said, "KLH's long-standing importance in vaccine development and immunology is gaining popular attention of late. Stellar appreciates the recent recognition for our industry-leading best practices and our dedication to ensure supply of KLH, a critical natural resource."